AF
CTXR icon

Amalgamated Financial’s Citius Pharmaceuticals CTXR Stock Holding History

Amalgamated Financial’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$25K Buy
+549
New +$21.7K ﹤0.01% 2673

Other funds holding CTXR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Amalgamated Financial's CTXR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Citius Pharmaceuticals (CTXR) in Q1 2022: 549 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #2673 among its holdings.

76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

  • Amalgamated Financial held 549 shares of Citius Pharmaceuticals worth $25K as of Q1 2022.
  • Citius Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Citius Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2673 holding.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.